Fig. 4From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trialCD31+ CXCR4+ expression in MNCs assessed by flow cytometry. Double positivity of CD31 and CXCR4 is higher for saxagliptin group at visit 2 and visit 3 in comparison to placebo group (p < 0.01)Back to article page